Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Convertible Debt (2016 - 2025)

Ironwood Pharmaceuticals' Convertible Debt history spans 11 years, with the latest figure at $199.2 million for Q1 2025.

  • For Q1 2025, Convertible Debt changed 0.34% year-over-year to $199.2 million; the TTM value through Mar 2025 reached $199.2 million, changed 0.34%, while the annual FY2024 figure was $199.0 million, 0.34% changed from the prior year.
  • Convertible Debt for Q1 2025 was $199.2 million at Ironwood Pharmaceuticals, roughly flat from $199.0 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $436.1 million in Q1 2021 and bottomed at $198.0 million in Q2 2023.
  • The 5-year median for Convertible Debt is $329.2 million (2021), against an average of $294.3 million.
  • The largest annual shift saw Convertible Debt grew 20.14% in 2022 before it plummeted 49.96% in 2024.
  • A 5-year view of Convertible Debt shows it stood at $337.3 million in 2021, then rose by 17.47% to $396.3 million in 2022, then plummeted by 49.95% to $198.3 million in 2023, then increased by 0.34% to $199.0 million in 2024, then rose by 0.09% to $199.2 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Convertible Debt are $199.2 million (Q1 2025), $199.0 million (Q4 2024), and $198.8 million (Q3 2024).